Chemotherapy-induced cardiotoxicity (CIC) is an emerging clinical problem with significant healthcare costs and no preventative therapies (1, 2). Identifying selective therapeutic targets in CIC is difficult, in part, because the mechanisms of drug toxicity vary between chemotherapeutics. For example, cardiotoxicity can be acute or chronic, transient or permanent, and can affect myocardial contractility, cardiomyocyte conduction or the myocardial vascular system (3). Thus, candidate CIC therapies would need to target many features involved in cardiac dysfunction, and additionally should not prevent chemotherapy-mediated tumor regression. Although most would agree that investing in new therapies that specifically target the tumor, while not affecting other normal tissues, including the heart would be ideal, this approach is currently impractical, as even the most selective cancer therapies have been associated with cardiotoxicity (1). For example, Bcr-Abl kinase is a specific gene fusion that causes chronic myeologenous leukemia (CML) (4), and although Bcr-Abl kinase inhibitors, including imatinib mesylate are effective in treating CML (5), they are also associated with cardiotoxicity in pre-clinical animal studies and patients (6), suggesting that alternative adjuvant therapies that can prevent, limit or improve CIC need to be developed. The most commonly used preventative therapy for CIC is dexrazoxane (7), and although dexrazoxane has shown some benefit in preventing CIC (7), it has also been associated with prevention of chemotherapy-induced tumor regression (8), and increased incidence in the development of certain types of cancer in pediatric patients (9, 10). In addition, current treatment guidelines for patients diagnosed with CIC often result in discontinuation of the chemotherapy (regardless of the tumor responsiveness) and initiation into standard heart failure treatment regimes (which include β-blockers and angiotensin inhibitors) (11). In both options, for either prevention or treatment of CIC, the myocardium appears to have precedence over the tumor, with patients receiving suboptimal care for their cancer. Rather than separating our treatment regime to focus either on heart failure or cancer, an ideal approach would look for common pathways identified in both tissues, with the aim to limit or improve chemotherapy-induced heart failure, but not prevent (or even enhance) chemotherapy-induced tumor regression. In this opinion article, we will discuss metabolic pathways that appear to be induced in both the failing heart and tumor, suggesting that metabolic therapies could provide an alternative approach for treating CIC, without hindering or potentially even improving chemotherapy-induced tumor regression.
In recent years several metabolic pathways have been identified in the failing myocardium, resulting in the emergence of metabolic therapies that appear to be beneficial against several forms of heart failure in both animals and patients (12, 13). The myocardium is the most energetically demanding organ of our body, and predominantly utilizes long-chain fatty acids and glucose as the primary substrates to generate adenosine triphosphate (ATP), which is required for myocardial contractility (14). In normal conditions, glucose is metabolized to pyruvate in the cytoplasm by glycolysis (GLY), generating ~2 ATP (14). Pyruvate can be further metabolized in the mitochondria to acetyl-CoA, the substrate for the Krebs' cycle, in a process termed glucose oxidation (GO), and this requires the pyruvate dehydrogenase complex (PDC) (14). Alternatively, long-chain fatty acids can also be metabolized in the mitochondria to generate acetyl-CoA via fatty acid β-oxidation (FAO) (14). The reducing equivalents NADH and FADH2 produced from the Krebs' cycle can enter the electron transport chain (ETC) to produce ~32 ATP (14). The normal myocardium generates the majority of its ATP (~60–90%) from mitochondrial fatty acid β-oxidation (FAO) and glucose oxidation (GO), with cytoplasmic GLY providing a minimal alternative energy-producing pathway (14, 15). Several studies have reported that a transition from a normal to failing myocardium is associated with a switch in energy metabolism from mitochondrial GO to cytoplasmic GLY (13–15). Furthermore, GLY appears to be uncoupled from GO, in part, because PDC is actively inhibited by pyruvate dehydrogenase kinase (PDK) (14). The increase in GLY (and uncoupling to GO) results in an increase in the production of lactate and protons (H+) in the cytoplasm. This buildup of H+ eventually results in a decrease in cardiac efficiency, since the cardiomyocytes utilize a large amount of ATP to restore ion homeostasis, at the expense of ATP-dependent contractility (14). Thus, this shift in energy metabolism impairs cardiac contractility and conductance.
A prominent metabolic transcription factor that has been shown to be important in the switch in energy metabolism from GO to GLY is hypoxia-inducible factor 1α (HIF1α) (16). HIF1α is a transcription factor that is induced in the failing myocardium, and is associated with increased expression of glucose transporters, glycolytic enzymes, and PDK (17–19). Thus, HIF1α can directly increase GLY (via increasing glucose uptake into the cell and increasing the levels of glycolytic enzymes) and inhibit GO (via the induction of PDK), resulting in decreased cardiac efficiency. Several studies have shown that coupling GLY with GO can improve cardiac function in several heart failure models. For example, inhibition of PDK with the small molecule compound dicholoracetate (DCA) improves cardiac function in both ischemic and afterload-induced heart failure models (20–24). Furthermore, inhibition of FAO with Ranolazine or Trimetazidine, which subsequently increase GO [via the Randle cycle; (25)], improves cardiac function in multiple preclinical heart failure models and in patients (26–29). Therefore, increasing GO (either directly with PDK inhibitors or indirectly with FAO inhibitors) appears to reverse the metabolic remodeling observed in the failing heart and improve cardiac efficiency and function. A recent study has implicated a similar metabolic remodeling in sunitinib-induced heart failure [i.e., increased GLY (30)], suggesting that therapeutically increasing GO in CIC would be beneficial in this form of heart failure as well. In addition, several chemotherapeutics, including anthracyclines or tyrosine kinase inhibitors are associated with cardiac metabolic dysfunction (30–38), providing further evidence that metabolic therapies could be beneficial against a variety of cardiotoxic chemotherapy agents.
Intriguingly, a similar metabolic remodeling has also been identified in cancer progression (39, 40). In 1927 Otto Warburg observed that most cancer cells utilized aerobic GLY, and this was associated with decreased mitochondrial respiration (41). It is now well described that cancer cells have a similar uncoupling of GLY with GO to the failing myocardium, however, unlike the failing myocardium, this metabolic profile provides cancer cells with a survival advantage (39, 42). For example, the increase in GLY in cancer results in an increase in other glycolytic branching pathways, including the pentose phosphate pathway or serine biosynthetic pathway, which generates nucleotides or amino acids, respectively, both required for cell proliferation (40, 43). Alternatively, the decrease in mitochondrial GO provides cancer cells with apoptosis resistance (19, 39, 44). The inhibition of PDC (and GO) in cancer cells is associated with an increase in the mitochondrial membrane potential, which subsequently increases the threshold for activation of the mitochondrial permeability transition pore and thus, mitochondrial dependent apoptosis (19, 39, 44). Similar to the failing myocardium, HIF1α is also induced in cancer cells and is associated with an increase in the expression of glucose transporters, glycolytic enzymes and PDK (resulting in suppressed mitochondrial GO). Inhibition of PDK (and increasing GO), with DCA in cancer cells results in decreased proliferation and enhanced mitochondrial-dependent apoptosis, resulting in decreased tumor growth in several pre-clinical animal models (19, 44–47), and in a small clinical trial in glioblastoma patients (48). Alternatively, other compounds that also increase GO, including the pyruvate kinase activator TEPP-46, has shown benefit against tumor progression (49). Taken together, these studies provide strong evidence that therapeutically increasing GO is a valid approach for decreasing tumor progression. In addition, our group had shown that increasing GO with DCA was sufficient to decrease HIF1α activity (44), providing a strong positive feedback loop that would potentiate the increase in the GO/GLY ratio, in cancer.
Recent evidence has also implicated HIF1α with the reductive glutamine pathway in cancer (50–52). The reductive glutamine pathway is associated with decreased GO, and provides cancer cells with sufficient mitochondrial substrates (i.e., citrate) to sustain lipogenesis, a critical requirement for proliferating cancer cells (50). Similarly the reductive glutamine pathway has also been implicated in right-sided heart failure, as well (53), and inhibition of this pathway has been shown to be beneficial against both heart failure and cancer progression (51–53). Intriguingly, enhancing GO has been shown to inhibit the reductive glutamine pathway (51, 53), suggesting that metabolic therapies which increase GO could have alternative benefits against heart failure and cancer progression, in addition to altering energy metabolism.
In conclusion, a similar metabolic profile (i.e., uncoupling of GLY with GO) appears to be prominent in both heart failure and cancer (see Figure 1). Therapeutically increasing GO in either the failing myocardium or tumor results in improved cardiac function or tumor regression, respectively, suggesting that a similar metabolic therapy could be beneficial in CIC. Although intriguing, much work is required to address if metabolic therapies could be advantageous against this emerging and prominent clinical condition.
Figure 1
Statements
Author contributions
All authors listed, have made substantial, direct and intellectual contribution to the work, and approved it for publication.
Funding
GS is supported by an Alberta Innovates Translational Health Chair in Cardio-Oncology and an Alberta and National New Investigator Award from Heart and Stroke Foundation of Canada, along with grants from the Canadian Institutes of Health Research and Mazankowski Alberta Heart Institute/Heart and Stroke Foundation of Alberta.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer SG and handling editor declared their shared affiliation.
References
1.
AlbiniAPennesiGDonatelliFCammarotaRDe FloraSNoonanDM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. (2010) 102:14–25. 10.1093/jnci/djp440
2.
NolanMTPlanaJCThavendiranathanPShawLSiLMarwickTH. Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity. Int J Cardiol. (2016) 212:336–45. 10.1016/j.ijcard.2016.02.137
3.
EwerMSEwerSM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. (2015) 12:620. 10.1038/nrcardio.2015.133
4.
GoldmanJMMeloJV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. (2001) 344:1084–86. 10.1056/NEJM200104053441409
5.
DrukerBJGuilhotFO'BrienSGGathmannIKantarjianHGattermannNet al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. (2006) 355:2408–17. 10.1056/NEJMoa062867
6.
KerkelaRGrazetteLYacobiRIliescuCPattenRBeahmCet al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. (2006) 12:908–16. 10.1038/nm1446
7.
LipshultzSERifaiNDaltonVMLevyDESilvermanLBLipsitzSRet al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. (2004) 351:145–53. 10.1056/NEJMoa035153
8.
SehestedMJensenPBSorensenBSHolmBFricheEDemantEJ. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol. (1993) 46:389–93. 10.1016/0006-2952(93)90514-W
9.
TebbiCKLondonWBFriedmanDVillalunaDDeAlarcon PAConstineLSet al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. (2007) 25:493–500. 10.1200/JCO.2005.02.3879
10.
SalzerWLDevidasMCarrollWLWinickNPullenJHungerSPet al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia (2010) 24:355–70. 10.1038/leu.2009.261
11.
ViraniSADentSBrezden-MasleyCClarkeBDavisMKJassalDSet al. Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. (2016) 32:831–41. 10.1016/j.cjca.2016.02.078
12.
NagoshiTYoshimuraMRosanoGMLopaschukGDMochizukiS. Optimization of cardiac metabolism in heart failure. Curr Pharm Des. (2011) 17:3846–53. 10.2174/138161211798357773
13.
DoenstTNguyenTDAbelED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. (2013) 113:709–24. 10.1161/CIRCRESAHA.113.300376
14.
LopaschukGDUssherJRFolmesCDJaswalJSStanleyWC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. (2010) 90:207–58. 10.1152/physrev.00015.2009
15.
SankaralingamSLopaschukGD. Cardiac energy metabolic alterations in pressure overload–induced left and right heart failure (2013 Grover Conference Series). Pulm Circ. (2015) 5:15–28. 10.1086/679608
16.
VanderHeiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. (2011) 10:671–84. 10.1038/nrd3504
17.
KimJWTchernyshyovISemenzaGLDangCV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. (2006) 3:177–85. 10.1016/j.cmet.2006.02.002
18.
SutendraGDromparisPPaulinRZervopoulosSHaromyANagendranJet al. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med. (2013) 91:1315–27. 10.1007/s00109-013-1059-4
19.
BonnetSArcherSLAllalunis-TurnerJHaromyABeaulieuCThompsonRet al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. (2007) 11:37–51. 10.1016/j.ccr.2006.10.020
20.
TaniguchiMWilsonCHunterCAPehowichDJClanachanASLopaschukGD. Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak. Am J Physiol Heart Circ Physiol. (2001) 280:H1762–9. 10.1152/ajpheart.2001.280.4.H1762
21.
UssherJRWangWGandhiMKeungWSamokhvalovVOkaTet al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res. (2012) 94:359–69. 10.1093/cvr/cvs129
22.
KatoTNiizumaSInuzukaYKawashimaTOkudaJTamakiYet al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail. (2010) 3:420–30. 10.1161/CIRCHEARTFAILURE.109.888479
23.
CarleyANTaglieriDMBiJSolaroRJLewandowskiED. Metabolic efficiency promotes protection from pressure overload in hearts expressing slow skeletal troponin I. Circ Heart Fail. (2015) 8:119–27. 10.1161/CIRCHEARTFAILURE.114.001496
24.
BersinRMWolfeCKwasmanMLauDKlinskiCTanakaKet al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J. Am. Coll. Cardiol. (1994) 23:1617–24. 10.1016/0735-1097(94)90665-3
25.
RandlePJGarlandPBHalesCNNewsholmeEA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet (1963) 1:785–9. 10.1016/S0140-6736(63)91500-9
26.
UndrovinasAIBelardinelliLUndrovinasNASabbahHN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. (2006) 17(Suppl. 1):S169–S77. 10.1111/j.1540-8167.2006.00401.x
27.
ChandlerMPStanleyWCMoritaHSuzukiGRothBABlackburnBet al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res. (2002) 91:278–80. 10.1161/01.RES.0000031151.21145.59
28.
FragassoGPerseghinGDeCobelli FEspositoAPalloshiALattuadaGet al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. (2006) 27:942–8. 10.1093/eurheartj/ehi816
29.
KantorPFLucienAKozakRLopaschukGD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. (2000) 86:580–8. 10.1161/01.RES.86.5.580
30.
MeredithLRJananiSYuantengLiDaleJHHowardOFHeinrichT. A PKM2 signature in the failing heart. Biochem Biophys Res Commun. (2015) 495:430–6. 10.1016/j.bbrc.2015.02.122
31.
DoroshowJHDaviesKJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. (1986) 261:3068–74.
32.
WallaceKB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol. (2003) 93:105–15. 10.1034/j.1600-0773.2003.930301.x
33.
DamianiRMMouraDJViauCMCaceresRAHenriquesJASaffiJ. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol. (2016) 90:2063–76. 10.1007/s00204-016-1759-y
34.
ForceTKrauseDSVanEtten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Cancer Rev. (2007) 7:332–44. 10.1038/nrc2106
35.
ZarkoBDominikSAlenaSOmidASabineSJuliaHet al. Radiation–induced signaling results in mitochondrial impairment in mouse heart at 4 weeks after exposure to X-rays. PLoS ONE (2011) 6:e27811. 10.1371/journal.pone.0027811
36.
Marie-LaureCrouchGaryKRudolphSNolanGEJasonHBielasDJMet al. Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects. PLoS ONE (2017) 12:e0181086. 10.1371/journal.pone.0181086
37.
AnaFilipa R-MEmiliaSMariade Lourdes BVeraMarisa C. The role of the metabolism of anticancer drugs in their induced-cardiotoxicity. Curr Drug Metabol. (2016) 17:75–90. 10.2174/1389200216666151103114926
38.
ZoltánVVargaPFLucasLPálP. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. (2015) 309:H1453–H67. 10.1152/ajpheart.00554.2015
39.
SutendraGMichelakisED. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol. (2013) 3:38. 10.3389/fonc.2013.00038
40.
VanderHeiden MGCantleyLCThompsonCB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324:1029–33. 10.1126/science.1160809
41.
WarburgOWindFNegeleinE. The metabolism of tumors in the body. J Gen Physiol. (1927) 8:519–30. 10.1085/jgp.8.6.519
42.
GatenbyRAGilliesRJ. Why do cancers have high aerobic glycolysis?Nat Rev Cancer (2004) 4:891–9. 10.1038/nrc1478
43.
LocasaleJWGrassianARMelmanTLyssiotisCAMattainiKRBassAJet al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. (2011) 43:869–74. 10.1038/ng.890
44.
SutendraGDromparisPKinnairdAStensonTHHaromyAParkerJMet al. Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer. Oncogene (2013) 32:1638–50. 10.1038/onc.2012.198
45.
CaoWYacoubSShiverickKTNamikiKSakaiYPorvasnikSet al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate (2008) 68:1223–31. 10.1002/pros.20788
46.
WongJYHugginsGSDebiddaMMunshiNCDeVivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol. (2008) 109:394–402. 10.1016/j.ygyno.2008.01.038
47.
MadhokBMYeluriSPerrySLHughesTAJayneDG. Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer (2010) 102:1746–52. 10.1038/sj.bjc.6605701
48.
MichelakisEDSutendraGDromparisPWebsterLHaromyANivenEet al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. (2010) 2:31ra4. 10.1126/scitranslmed.3000677
49.
AnastasiouDYuYIsraelsenWJJiangJKBoxerMBHongBSet al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. (2012) 8:839–47. 10.1038/nchembio.1060
50.
AnastasiouDCantleyLC. Breathless cancer cells get fat on glutamine. Cell Res. (2012) 22:443–6. 10.1038/cr.2012.5
51.
MetalloCMGameiroPABellELMattainiKRYangJHillerKet al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature (2011) 481:380–4. 10.1038/nature10602
52.
MullenARWheatonWWJinESChenPHSullivanLBChengTet al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 481:385–8. 10.1038/nature10642
53.
PiaoLFangYHParikhKRyanJJTothPTArcherSL. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med. (2013) 91:1185–97. 10.1007/s00109-013-1064-7
Summary
Keywords
cardiotoxicity, cardiac metabolism, heart failure, altered metabolism, Warburg effect, cardio-oncology
Citation
Saleme B and Sutendra G (2018) A Similar Metabolic Profile Between the Failing Myocardium and Tumor Could Provide Alternative Therapeutic Targets in Chemotherapy-Induced Cardiotoxicity. Front. Cardiovasc. Med. 5:61. doi: 10.3389/fcvm.2018.00061
Received
03 April 2018
Accepted
15 May 2018
Published
11 June 2018
Volume
5 - 2018
Edited by
Thomas Pulinilkunnil, Dalhousie University, Canada
Reviewed by
Scott A. Grandy, Dalhousie University, Canada; Beshay Zordoky, College of Pharmacy, University of Minnesota, United States
Updates
Copyright
© 2018 Saleme and Sutendra.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gopinath Sutendra sutendra@ualberta.ca
This article was submitted to Cardiovascular Metabolism, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.